| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Experiments showed that intravenous injection of pure carbon suspension into rabbits did not cause eye inflammation, although carbon particles were deposited in the blood vessels. |
|---|---|
| Toxicity/Toxicokinetics |
Non-Human Toxicity Values
Oral LD50 in rats > 10,000 mg/kg; Intravenous LD50 in mice 440 mg/kg |
| References | |
| Additional Infomation |
According to the International Agency for Research on Cancer (IARC) of the World Health Organization, carbon black (airborne particulate matter) may be carcinogenic. Activated carbon is a black granular material processed to enhance its adsorption capacity. It may spontaneously combust if not properly cooled after production. Carbon of animal or plant origin is a black powder or granules mixed with tar or starch and a water binder, pressed into regular blocks or briquettes. It heats slowly and is flammable in air, especially in humid conditions. Carbon nanotubes are fullerene-like nanostructures composed of graphene cylinders. Their ends are closed by pentagonal rings. Carbon is a nonmetallic tetravalent element with the symbol C, atomic number 6, and atomic weight 12. Carbon is a mineral. See also: carbon black (with subclasses); graphite (with subclasses). Activated carbon (with subclasses)...see more...
|
| Molecular Formula |
C
|
|---|---|
| Exact Mass |
12
|
| CAS # |
7440-44-0
|
| Related CAS # |
Carbon-13C;14762-74-4
|
| PubChem CID |
5462310
|
| Appearance |
Steel gray to black greasy feeling solid.
|
| Density |
~1.7 g/mL at 25 °C(lit.)
|
| Boiling Point |
500-600 °C(lit.)
|
| Melting Point |
Melting point equals greater than 3500 °C
; MW: 760.642 Yellow needles of plates. MP: >280 °C. Soluble in organic solvents /Fullerene-60/
; MW: 840.749. Red-brown solid. MP: >280 °C. Soluble in benzene, toluene /Fullerene-70/
; >3500 °C
; 4489 °C
; 6602 °F (Sublimes)
|
| Flash Point |
>230 °F
|
| Vapour Pressure |
<0.1 mm Hg ( 20 °C)
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
1
|
| Complexity |
0
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[C]
|
| InChi Key |
OKTJSMMVPCPJKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C
|
| Chemical Name |
carbon
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06608277
Conditions:Posttraumatic Headache|Posttraumatic Stress DisorderLink: https://clinicaltrials.gov/ct2/show/NCT01709292
Conditions:Thyroid CancerLink: https://clinicaltrials.gov/ct2/show/NCT06141473
Conditions:Multiple Sclerosis
Title:Measuring Acute Drug Demand in Humans
Status:Suspended
updateDate:2026-02-18
Ctid:NCT05829655
Link: https://clinicaltrials.gov/ct2/show/NCT05829655
Conditions:Opioid Use Disorder|Opioid DependenceLink: https://clinicaltrials.gov/ct2/show/NCT05471479
Conditions:Charcoal, Decontamination, PoisoningLink: https://clinicaltrials.gov/ct2/show/NCT07299877
Conditions:Brachial Plexus BlocksLink: https://clinicaltrials.gov/ct2/show/NCT07220031
Conditions:Osmolality Disturbance|Lab InterferenceLink: https://clinicaltrials.gov/ct2/show/NCT02969746
Conditions:Anticoagulants; Circulating, Hemorrhagic DisorderLink: https://clinicaltrials.gov/ct2/show/NCT06790290
Conditions:Pneumococcal Disease, InvasiveLink: https://clinicaltrials.gov/ct2/show/NCT06906874
Conditions:End Stage Renal Disease (ESRD)|CKD 5D, Hemodialysis|CKD-MBD - Chronic Kidney Disease Mineral and Bone DisorderLink: https://clinicaltrials.gov/ct2/show/NCT07108881
Conditions:Cesarean Section Complications|Spinal Anesthesia|Hypotension|Hypovolemia|Sympathetic Blockade|Fluid LoadingLink: https://clinicaltrials.gov/ct2/show/NCT07096765
Conditions:Nerve BlockLink: https://clinicaltrials.gov/ct2/show/NCT06806007
Conditions:Pulmonary Dysfunction|Spastic DiaplegiaLink: https://clinicaltrials.gov/ct2/show/NCT02813460
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06422403
Conditions:Carcinoma, Hepatocellular|Gastric Adenocarcinoma|GastroEsophageal Cancer|Oesophageal Cancer|Non-small Cell Lung Cancer|Head and Neck Squamous Cell CarcinomaLink: https://clinicaltrials.gov/ct2/show/NCT06579066
Conditions:Chronic Kidney Disease|Uremic PruritusLink: https://clinicaltrials.gov/ct2/show/NCT06491485
Conditions:Postoperative PainLink: https://clinicaltrials.gov/ct2/show/NCT06219967
Conditions:OverdoseLink: https://clinicaltrials.gov/ct2/show/NCT06209372
Conditions:Efficiency|Spinal Anesthesia|BlockLink: https://clinicaltrials.gov/ct2/show/NCT06355960
Conditions:Drug Use|DexmedetomidineLink: https://clinicaltrials.gov/ct2/show/NCT05752734
Conditions:Anesthesia|Analgesia|Acute PainLink: https://clinicaltrials.gov/ct2/show/NCT04713631
Conditions:Crohn's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04631107
Conditions:Obstructive Sleep ApneaLink: https://clinicaltrials.gov/ct2/show/NCT04767776
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05540431
Conditions:Uremic ToxinLink: https://clinicaltrials.gov/ct2/show/NCT03762343
Conditions:Posterior Fossa TumorLink: https://clinicaltrials.gov/ct2/show/NCT03802487
Conditions:Type 2 Diabetes Mellitus|Healthy SubjectsLink: https://clinicaltrials.gov/ct2/show/NCT04928950
Conditions:Lung CancerLink: https://clinicaltrials.gov/ct2/show/NCT04540848
Conditions:Post Operative PainLink: https://clinicaltrials.gov/ct2/show/NCT03572062
Conditions:Respiratory Tract InfectionLink: https://clinicaltrials.gov/ct2/show/NCT04739917
Conditions:Malaria, VivaxLink: https://clinicaltrials.gov/ct2/show/NCT03311373
Conditions:Chronic Obstructive Pulmonary DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04311645
Conditions:Chronic Kidney Disease stage3Link: https://clinicaltrials.gov/ct2/show/NCT01336647
Conditions:PediculosisLink: https://clinicaltrials.gov/ct2/show/NCT03668964
Conditions:Healthy VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT04135534
Conditions:Post Operative Pain|Opioid Side EffectsLink: https://clinicaltrials.gov/ct2/show/NCT03718390
Conditions:Gastric Retention|HealthyLink: https://clinicaltrials.gov/ct2/show/NCT01389752
Conditions:Depressive Disorder, MajorLink: https://clinicaltrials.gov/ct2/show/NCT01139164
Conditions:Hematological MalignanciesLink: https://clinicaltrials.gov/ct2/show/NCT02426632
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT02083068
Conditions:MalariaLink: https://clinicaltrials.gov/ct2/show/NCT01231568
Conditions:CancerLink: https://clinicaltrials.gov/ct2/show/NCT00495274
Conditions:Sleep Initiation and Maintenance DisordersLink: https://clinicaltrials.gov/ct2/show/NCT00548769
Conditions:Multiple SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT03202459
Conditions:Postoperative Complications|Postoperative Nausea and VomitingLink: https://clinicaltrials.gov/ct2/show/NCT01424462
Conditions:Multiple Sclerosis, Relapsing-RemittingLink: https://clinicaltrials.gov/ct2/show/NCT02737371
Conditions:Invasive AspergillosisLink: https://clinicaltrials.gov/ct2/show/NCT02691325
Conditions:Pulmonary Disease, Chronic ObstructiveLink: https://clinicaltrials.gov/ct2/show/NCT03033667
Conditions:Metabolism DisorderLink: https://clinicaltrials.gov/ct2/show/NCT01257191
Conditions:Hypersensitivity, Immediate|Atopic HypersensitivityLink: https://clinicaltrials.gov/ct2/show/NCT01409369
Conditions:Healthy VolunteerLink: https://clinicaltrials.gov/ct2/show/NCT01796717
Conditions:Nosocomial PneumoniaLink: https://clinicaltrials.gov/ct2/show/NCT02003313
Conditions:MeningitisLink: https://clinicaltrials.gov/ct2/show/NCT01226771
Conditions:Hepatitis CLink: https://clinicaltrials.gov/ct2/show/NCT01863888
Conditions:Multiple SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT01679028
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT00823264
Conditions:Phenytoin ToxicityLink: https://clinicaltrials.gov/ct2/show/NCT01489995
Conditions:Fabry DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01838967
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT01580033
Conditions:Meningitis|InfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT01199627
Conditions:Hip Replacement, TotalLink: https://clinicaltrials.gov/ct2/show/NCT01737437
Conditions:Neurosurgical PatientsLink: https://clinicaltrials.gov/ct2/show/NCT00211562
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT01428908
Conditions:Group A, C Polysaccharide Meningitis|Type b Haemophilus InfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT00419146
Conditions:Schizophrenia|Schizophreniform Disorders|Schizoaffective Disorder|Psychotic DisordersLink: https://clinicaltrials.gov/ct2/show/NCT00592137
Conditions:Obesity|Energy MetabolismProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
